Objective-Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1), a secreted and surface-exposed glycoprotein on activated platelets, promotes platelet-platelet interaction and supports platelet-matrix adhesion. Its plasma level is a biomarker of platelet activation in acute thrombotic diseases. However, the exact roles of plasma SCUBE1 in vivo remain undefined. Approach and Results-We generated new mutant (Δ) mice lacking the soluble but retaining the membrane-bound form of SCUBE1. Plasma SCUBE1-depleted Δ/Δ mice showed normal hematologic and coagulant features and expression of major platelet receptors, but Δ/Δ platelet-rich plasma showed impaired platelet aggregation in response to ADP and collagen treatment. The addition of purified recombinant SCUBE1 protein restored the aggregation of platelets in Δ/Δ platelet-rich plasma and further enhanced platelet aggregation in +/+ platelet-rich plasma. Plasma deficiency of SCUBE1 diminished arterial thrombosis in mice and protected against lethal thromboembolism induced by collagen-epinephrine treatment. Last, antibodies directed against the epidermal growth factor-like repeats of SCUBE1, which are involved in trans-homophilic protein-protein interactions, protected mice against fatal thromboembolism without causing bleeding in vivo.
S CUBE1 (signal peptide-CUB [complement protein C1r/ C1s, Uegf, and Bmp1]-EGF [epidermal growth factor] domain-containing protein 1) is the founding member of a secreted and membrane-associated SCUBE protein family. 1, 2 To date, 3 different members have been identified and are evolutionarily conserved in zebrafish, mice, and humans. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] These genes code for proteins of ≈1000 amino acids forming 5 domains: an NH 2 -terminal signal peptide sequence, 9 tandem repeats of EGF-like motifs, a large N-glycosylated spacer region followed by 3 cysteine-rich (CR) repeats, and one CUB domain at the COOH terminus. 2, 5, 10 When overexpressed in human embryonic kidney cells, recombinant SCUBE1 proteins form oligomers, which are either secreted into the conditioned medium or remain tethered to the cell surface where it behaves like a peripheral membrane (not membrane-spanning) protein. 2 Thus, SCUBE1 may have distinct functions depending on its distribution as a soluble or membrane-associated protein.
We and others have shown that Scube1 is expressed during mouse development and in adult endothelial cells. 1, 2 However, SCUBE1 protein is also expressed in platelets. 13 SCUBE1 is stored within the α-granules of resting platelets, translocated to the platelet surface upon activation by thrombin, proteolytically released as smaller soluble fragments, and incorporated into thrombus. 13 In addition, immunohistochemical analysis showed the deposition of SCUBE1 in the subendothelial matrix of human advanced atherosclerotic lesions. 13 Similar to the known functions of the EGF-like domains in mediating homophilic protein-protein interactions as well as cell adhesion, 14, 15 the NH 2 -terminal EGF-like domain repeats of SCUBE1 are also capable of promoting platelet-platelet interaction or supporting platelet-matrix adhesion in vitro. 13, 16 Platelet activation and aggregation are primary reactions in arterial thrombosis and, accordingly, are responsible for the ischemic complications of acute thromboembolic diseases. [17] [18] [19] Our recent clinical study showed that plasma SCUBE1 concentration is significantly elevated and is a potential biomarker of platelet activation in acute coronary syndrome and acute ischemic stroke. 20 In addition, plasma SCUBE1 levels are higher in hemodialysis or hypertensive patients. 21, 22 Furthermore, a genetic variant of SCUBE1 gene is associated with enhanced risk of venous thromboembolism. 23 However, the precise functions of soluble SCUBE1 in thromboembolic vascular diseases remain largely unknown.
In this study, we generated plasma SCUBE1-depleted mutant (Δ/Δ) mice to evaluate the pathophysiological roles of soluble SCUBE1 in vivo. Our results show that plasma SCUBE1 plays an important role in platelet aggregation and thrombus formation. In addition, genetic loss of soluble SCUBE1 or anti-SCUBE1 antibodies protected mice against fatal thromboembolism with a modest effect on bleeding. These data suggest that inhibition of plasma SCUBE1 might provide a novel therapeutic target/strategy to safely block thrombosis.
Materials and Methods
Materials and Methods are available in the online-only Supplement.
Results

Deletion of a Part of the Spacer Region and the Entire CR Repeats of SCUBE1 Prevents Its Secretion
To explore the biological function of plasma SCUBE1 in vivo, we first designed and characterized a mutated recombinant protein with deficiency in producing the soluble form of SCUBE1. Because our previous studies indicated that the spacer region and CR repeats are involved in the secretion and membrane association of SCUBE1 and the COOH-terminal CUB domain is essential for embryonic brain development, 16 we constructed a deletion mutant specifically lacking a part of the spacer region and the entire 3 CR repeats but preserving the CUB domain at the COOHterminus (named SCUBE1-Δ; see Figure 1A ). To test its secretion and membrane-anchoring properties, we overexpressed the SCUBE1-Δ protein in human embryonic kidney-293T cells. Western blot analyses showed that SCUBE1-Δ indeed completely lost its secretory ability ( Figure 1B) , but retained its cell-surface expression ( Figure 1C ) at a lower level because SCUBE1-Δ still contains the NH 2 -terminal part of the spacer region with a basic amino-acid stretch (amino acids 500 to 550) that is responsible for its membrane association through an electrostatic interaction with the acidic membrane phospholipids (unpublished data). Of note is that SCUBE1-Δ can form an oligomeric complex with itself and other SCUBE protein members when overexpressed in human embryonic kidney-293T cells and determined by a pull-down assay ( Figure I in the onlineonly Data Supplement).
Generation of a New Genetic Mutant Mouse Strain With Deficiency in Producing Plasma SCUBE1
Based on the in vitro deletion data, we next generated a targeting vector containing a loxP-flanked neomycin-resistant (Neo) cassette inserted in the Scube1 intron 18 and an additional loxP site in the upstream intron 14 of the gene ( Figure IIA in the online-only Data Supplement). Successful targeting of embryonic stem cells with this vector resulted in a conditional allele including the Neo cassette. Additional Cre-mediated recombination in embryonic stem cells deleted the Neo cassette and produced a conditional allele (Scube1 Flox ) that introduced 2 loxP sites flanking exons 15 to 18 encoding a part of the spacer region and the complete 3 CR repeat motifs of Scube1 ( Figure  IIA -IIC in the online-only Data Supplement). Heterozygous global Scube1 Δ/+ mice were generated by crossing male protamine (Prm)-Cre; Scube1 Flox/+ mice to wild-type female mice. Mice homozygous for the wild-type (+/+) allele or the targeted (Δ/Δ) allele were obtained by interbreeding the heterozygous (Δ/+) offspring and were born with the expected Mendelian ratio ( Figure IID in the online-only Data Supplement).
Reverse transcription-polymerase chain reaction analyses of platelet mRNA followed by direct sequencing of the PCR product confirmed that the coding sequences for a portion of the spacer region and the 3 CR repeats (exons 15-18) were successfully deleted, yet the COOH-terminal CUB domain was transcribed via in-frame coding in Δ/Δ mouse platelets ( Figure 1D , left). In addition, the mRNA expression of other Scube genes (Scube2 and Scube3) remained unchanged between +/+ and Δ/Δ mice ( Figure 1D , left). Because anti-SCUBE1 antibodies were ineffective in detecting endogenous mouse SCUBE1 protein expression by immunoblotting, we first used confocal immunofluorescent staining with anti-CUB specific antibody to verify the expression of SCUBE1-wildtype or Δ mutant protein in α-granules under high magnification ( Figure III in the online-only Data Supplement). In addition, immunostaining using anti-CR specific antibody confirmed a complete absence of these 3 CR repeats but conservation of the CUB domain (anti-CUB immunostaining) in Δ/Δ platelets ( Figure 1D , right). Consistent with previous in vitro studies ( Figure 1B ), in +/+ mice the plasma concentration of SCUBE1 was ≈150 ng/mL, whereas soluble SCUBE1 was undetectable in Δ/Δ mice, and both wild-type and Δ protein could be released from α-granules and tether on the platelet surface upon activation that could be suppressed by inhibiting platelet secretion by aspirin ( Figure IV Because platelet endothelial aggregation receptor-1 (PEAR1), a novel EGF-like repeat-containing transmembrane receptor, is expressed on the platelet surface and involved in platelet contact-induced activation. 24 We then performed further analysis of the interaction between PEAR1 and SCUBE1 by using a variety of SCUBE1 deletion constructs containing the EGF-like repeats, the spacer, the CR, or the CUB domain, respectively ( Figure V the adhesive module of the EGF-like repeats and the CUB domain of SCUBE1 can interact with PEAR1. These Δ/Δ mutant mice showed normal development, survival, and reproduction and no spontaneous bleeding or thrombosis. In addition, blood cell counts (including platelets) and hematologic and coagulation parameters, as well as protein or mRNA levels of major platelet surface receptors, including glycoprotein VI, glycoprotein IX, glycoprotein Ia (α2), β3 integrin, and ADP receptors (P2Y 1 and P2Y 12 ), were similar between +/+ and Δ/Δ mice (Table II and Figure VI in the online-only Data Supplement). This indicates that SCUBE1 is not required for the development of hematopoietic lineages, including the formation and maturation of platelets.
Platelet Aggregation Was Impaired in Plasma SCUBE1-Deficient Δ/Δ Platelet-Rich Plasma (PRP) Compared With +/+ PRP
ADP, collagen, and thrombin are the major platelet activators at the sites of vascular injury. 25 To determine the role of plasma SCUBE1 in platelet function, we first isolated PRP and measured platelet aggregation in response to ADP, collagen, and the thrombin agonist PAR-4 peptide ( Figure 2 ). With PAR-4 peptide (50-250 μmol/L), platelet aggregation was indistinguishable in PRP samples from +/+ and Δ/Δ mice ( Figure 2 ; Figure VII in the online-only Data Supplement). However, in response to ADP at 5 and 10 μmol/L or collagen at a low concentration, 2.5 μg/mL, platelets in PRP from Δ/Δ mice reproducibly aggregated less than that from +/+ mice. All agonists induced a comparable activation-dependent change from discoid to spherical shape in +/+ and Δ/Δ platelets, which can be seen as a transient upward deflection in the aggregation traces with the addition of agonists ( Figure 2 ). Therefore, plasma SCUBE1 is critical for a maximal response to ADP or a low concentration of collagen but not for the initial shape change after agonist stimulation.
Washed Δ/Δ Platelets Show Normal Morphological Features, Aggregation, and Signaling
To determine whether impaired PRP aggregation was due to an intrinsic morphological or signaling abnormality in platelets, we next prepared washed platelets from +/+ and Δ/Δ mice for ultrastructural and aggregation assays. Electron microscopy revealed no apparent differences in ultrastructure or the numbers of αor dense granules between +/+ and Δ/Δ platelets ( Figure  VIIIA in the online-only Data Supplement). In addition, ADP or collagen-induced aggregations of washed platelets were Deletion of a part of the spacer region and entire cysteine-rich (CR) repeats prevent its secretion. A, Domain structure of signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) wild-type (WT) and Δ mutant protein. A FLAG epitope tag was added immediately after the signal peptide sequence at the NH 2 terminus for easy detection. Locations of the polymerase chain reaction (PCR) primers and the corresponding immunogen for anti-CR or anti-CUB antibodies are marked. B, SCUBE1-Δ mutant is a secretion-deficient protein. HEK-293T cells were transfected with the indicated expression plasmid DNA. Two days after transfection, protein samples from the conditioned medium or cell lysates were immunoprecipitated with anti-FLAG antibody, separated by SDS-PAGE, and transferred to polyvinylidene difluoride membranes. Recombinant SCUBE1 proteins were detected by western blotting using anti-FLAG antibody. C, Cell surface expression of SCUBE1-Δ mutant. HEK-293T cells were transiently transfected with an empty vector (Vector) or the expression plasmid encoding FLAG epitope-tagged SCUBE1 WT or Δ mutant (Δ). Two days after transfection, cells transfected as above were stained with anti-FLAG antibody to determine cell surface expression. D, Correct targeting of the Δ allele at the mRNA and protein level. Reverse transcription (RT)-PCR analysis verified the mRNA expression of SCUBE1-Δ in Δ/Δ platelets and mRNA expression of Scube2 and Scube3 remained unaltered. In addition, the expression of CD45 or glycoprotein Ibα was verified and used as marker genes for leukocytes or platelets, respectively (left panels). Likewise, expression of SCUBE1-Δ protein lacking the entire 3 CR repeats but retaining the CUB domain in Δ/Δ platelets was confirmed by immunofluorescent staining using the domain-specific antibody as indicated (right panels) in isolated platelets adhered on fibrinogen-coated glass slides. Note that +/+ platelets were positive for both anti-CR and anti-CUB staining, and Δ/Δ platelets were only positive for anti-CUB staining. Control IgG was used as a negative staining control. Bar, 2 μm. CR indicates cysteine-rich repeats; CUB, CUB domain; E, epidermal growth factor-like domain; IP, immunoprecipitation; SP, signal peptide; and WB, Western blot analysis. . In agreement with this finding, flow cytometry showed that the active conformation of α IIb β 3 integrin induced by inside-out activation and the surface exposure of fibrinogen, von Willebrand factor, or P-selectin caused by α-granule secretion in response to agonist stimulation was virtually identical between +/+ and Δ/Δ platelets ( Figure VIIIB in the online-only Data Supplement). Likewise, the secretion of platelet dense granules as determined by measuring ATP release after activation was comparable between +/+ and Δ/Δ platelets (data not shown).
Plasma SCUBE1 Is Involved in Platelet Aggregation
Because intrinsic platelet structure and signaling seemed normal in Δ/Δ mice (Figures VIII and X in the online-only Data Supplement), we further evaluated whether plasma SCUBE1 is involved in agonist-stimulated aggregation. We performed platelet and plasma exchange studies with washed platelets from +/+ or Δ/Δ mice resuspended in platelet-poor plasma (PPP) from either genotype. Interestingly, +/+ platelets aggregated less in SCUBE1-depleted (Δ/Δ) PPP than in SCUBE1positive (+/+) PPP ( Figure 3A, left) . Conversely, Δ/Δ platelets aggregated more in +/+ PPP than in Δ/Δ PPP ( Figure 3A,  right) . These data indicate that plasma SCUBE1 is involved in platelet aggregation. To further confirm that the impaired aggregation in Δ/Δ mice was directly attributable to plasma deficiency of SCUBE1, we evaluated the effect of recombinant murine SCUBE1 (rSCUBE1) on platelet aggregation by adding rSCUBE1 protein in vitro. Although rSCUBE1 at concentrations ≤5 μg/mL had no effect on shape change, aggregation and agonist-induced signaling of +/+ platelets ( Figure XI in the online-only Data Supplement), the addition of rSCUBE1 at normal plasma level (150 ng/mL) was sufficient to restore the defective aggregation of Δ/Δ PRP in response to ADP ( Figure 3C ). Of note, the magnitude of platelet aggregation in Δ/Δ PRP samples with rSCUBE1 was rescued to the level in +/+ PRP samples (Figure 2A ) or the level in Δ/Δ platelets mixed with +/+ PPP ( Figure 3A ). In addition, rSCUBE1 further enhanced ADP-induced aggregation in +/+ PRP but not when α IIb β 3 function was inhibited ( Figure XII in the onlineonly Data Supplement).
To examine whether the EGF-like repeats are participated in promoting homophilic cell-cell aggregation, we then evaluated the effects of a glutathione S-transferase (GST) fusion protein containing the EGF-like repeats (GST-S1-E4-9) on the aggregating property of a stable cell line with surface overexpression of the EGF-like repeats of SCUBE1 (S1-E4-9) by cell aggregation assay. Monolayer cultures of the parental (control) or the transfected stable cell line (S1-E4-9) were dissociated into single cells and allowed to aggregate in suspension culture together with GST or GST-S1-E4-9 protein, respectively. When the suspensions were gently shaken, cells expressing S1-E4-9 tended to aggregate in the presence of GST-S1-E4-9 (≈40%) but not GST alone (≈5%), whereas the parental control cells aggregated poorly in suspension (<3%) ( Figure XIII in the online-only Data Supplement). These data suggested that the EGF-like repeats of SCUBE1 is capable of promoting the cell aggregation, possibly through trans-homophilic interactions and cross-linking the surface-expressed SCUBE1 proteins. However, soluble SCUBE1 could not compete with fibrinogen binding to activated platelets, suggesting that SCUBE1 may not bind activated α IIb β 3 integrin ( Figure XIV in the online-only Data Supplement). Overall, these findings are in agreement with our previous studies in humans 13, 16 and indicate that soluble SCUBE1 is an adhesive molecule, which cross-links adjacent activated platelets, thus promoting aggregation and stabilizing aggregates.
Δ/Δ Mice Are Protected Against Thrombosis and Have a Slightly Prolonged Bleeding Time
We then investigated the role of soluble SCUBE1 in platelet function by assessing thrombus formation in vitro. A wholeblood perfusion assay was performed over collagen-coated surfaces at a high shear rate of 1000 s −1 (Figure 4 ). After 3 minutes of perfusion, the area covered by thrombi was 27.6±4.1% for +/+ mice and 14.5±2.2% for Δ/Δ mice (47% lower than +/+; P<0.01). Similarly, the thrombus volume obtained from Δ/Δ mice was 56% smaller than that for +/+ mice (1.97±0.17 versus 4.47±0.8 μm 3 ×10 6 ; P<0.01). Interestingly, transfer of +/+ plasma can restore impaired thrombus formation in Δ/Δ mice (Figure 4 ). It is noteworthy that the addition of tirofiban (an α IIb β 3 inhibitor) markedly suppressed in vitro thrombus formation by +/+ or Δ/Δ platelets (data not shown). These data suggest that plasma SCUBE1 is important for platelet cross-linking (thrombus formation) in vitro under arterial shear conditions. Furthermore, we used 2 thrombosis models to determine the in vivo effects of plasma SCUBE1 deficiency. In the first model, we induced platelet-and fibrin-rich thrombus formation by ferric chloride injury and denudation of the carotid artery. 27 The size of arterial thrombus in Δ/Δ mice was 35% less on average than in +/+ mice (P<0.05; Figure 5A-5C ). Next, we used a model of platelet-dependent intravascular thrombosis and fatal pulmonary embolism induced by systemic intravenous injection of a mixture of collagen (0.3 mg/kg) and epinephrine (60 μg/kg). All +/+ mice died within 8 minutes after injection, whereas the survival rate for Δ/Δ mice was ≈60% (P<0.05 compared with +/+ mice; Figure 5D ). Thus, thrombus formation in Δ/Δ mice did not develop as rapidly or as extensively as in +/+ mice. Indeed, macroscopic and histological analysis revealed widespread pulmonary thromboembolism in +/+ mice ( Figure 5E ) but not in surviving Δ/Δ mice ( Figure 5F ). Thus, loss of plasma SCUBE1 significantly protected mice against arterial thrombosis.
Hemostasis involves both platelet aggregation and blood coagulation. To test whether the defect in plasma SCUBE1 affected hemostasis, we measured bleeding times in mice after tail-tip amputation ( Figure 5G) . The mean bleeding time in +/+ mice was 65±5.6 seconds (n=24), whereas bleeding was highly variable and mildly prolonged in Δ/Δ mice (140±17.5 seconds, n=24, P<0.05). To determine whether a defect in coagulation contributed to this increase in bleeding, we assessed activated partial thromboplastin time and prothrombin time as indices of intrinsic and extrinsic coagulation pathways, respectively. Neither activated partial thromboplastin time nor prothrombin time was altered in Δ/Δ mice ( Table II in the online-only Data Supplement). Thus, plasma SCUBE1 has an important function in hemostasis mediated by platelet aggregation, not coagulation.
Infusion of SCUBE1 Antibodies Protects Mice Against Fatal Thromboembolism
To examine whether blocking plasma SCUBE1 might be useful to prevent thrombosis, we studied the effect of specific antibodies against SCUBE1 on platelet aggregation in vitro and on thromboembolism in vivo. We used monoclonal antibodies raised specifically against the EGF-like repeats of SCUBE1 ( Figure XVB in the online-only Data Supplement), the domain which is involved in reciprocal and lateral interactions between SCUBE1 proteins in homophilic adhesions. 16 In contrast to the isotype-matched control antibody, the anti-SCUBE1-neutralizing antibody blocked the SCUBE1-mediated cell aggregation in a transfected cell line and ristocetin-induced platelet agglutination ( Figure XVF -XVH in the online-only Data Supplement). Moreover, the SCUBE1-neutralizing antibody protected +/+ mice against fatal thromboembolism induced by collagen and epinephrine (60% survival, Figure 6A ). Consistently, SCUBE1 antibody treatment also significantly reduced arterial thrombosis formation induced by ferric chloride injury ( Figure XVI in the online-only Data Supplement). Injection of saline or the isotype control antibody was ineffective in preventing fatal thromboembolism or arterial thrombosis in +/+ mice ( Figure 6A-6D ; Figure XVI in the online-only Data Supplement). In addition, SCUBE1-antibody-injected mice showed no sign of bleeding ( Figure 6E ). Together, these results indicate that functional neutralization of plasma SCUBE1 can effectively prevent thrombosis.
Discussion
Despite its original discovery in the endothelium, 2 SCUBE1 is also highly expressed in platelets. 13 When overexpressed in human embryonic kidney-293T cells, recombinant SCUBE1 is a secreted glycoprotein that forms an oligomeric complex tethered to the cell surface. 2, 16 Consistent with the well-recognized role of the EGF-like domain in mediating homophilic cell-cell interaction and adhesion, 14, 28 our previous studies showed that protein fragments containing the NH 2 -terminal EGF-like repeats of SCUBE1 can enhance platelet adhesion and ristocetin-induced platelet agglutination. 13 In addition, clinical studies by us and others showed significantly elevated plasma SCUBE1 content in patients with acute coronary syndrome, acute ischemic stroke, hypertension, and hemodialysis. [20] [21] [22] Thus, plasma SCUBE1 is a potential biomarker of platelet activation in acute thrombotic diseases. 20 However, whether soluble SCUBE1 has a pathological role in thrombogenesis during progression of acute thromboembolic diseases remains largely unknown.
In this study, we provide genetic evidence that soluble plasma SCUBE1 is not only a marker but also an active participant of thrombosis. Plasma SCUBE1-deficient Δ/Δ mice were protected against arterial thrombosis but did not show spontaneous bleeding. The antithrombotic mechanism of plasma deficiency of SCUBE1 was at least in part attributed to defective platelet aggregation. Of note, the antithrombotic effect of lack of plasma SCUBE1 is comparable with that of aspirin when assayed in the same thromboembolism model. 29 Soluble SCUBE1 did not directly stimulate resting platelets, but it augmented the aggregation in response to known platelet agonists such as ADP ( Figure XII in the online-only Data Supplement). Intriguingly, use of neutralizing antibodies against the EGF-like repeats at the NH 2 terminus of SCUBE1 protects mice against lethal thromboembolism without causing spontaneous bleeding. It is worth noting that tail bleeding time is unaltered after antibody treatment ( Figure 6E ), whereas it is modestly increased in Δ/Δ mice ( Figure 5G ). This difference between these 2 experiments may be the result of incomplete neutralization of plasma SCUBE1 by antibody treatment in vivo as opposed to a complete genetic ablation.
Although the specific binding target(s) for the released SCUBE1 remains to be identified, our in vitro pull-down assay showed that SCUBE1 can interact with PEAR1 through its EGF-like repeats and the CUB domain, suggesting PEAR1 as a potential receptor for SCUBE1 binding. However, further studies are required to verify this hypothesis and elucidate its signaling relevance in platelet biology. Interestingly, surfacebound SCUBE1 can be induced to form cell aggregates by the addition of recombinant SCUBE1 protein fragment containing the EGF-like repeats ( Figure XIII in the online-only Data Supplement). In agreement with these findings, rSCUBE1 protein further enhanced ADP-stimulated platelet aggregation ( Figure XII in the online-only Data Supplement). Together, our data suggest that soluble SCUBE1 acts through its EGFlike domain to form an oligomeric structure as a key adhesive protein forming trans-homophilic bridges between the surface-bound SCUBE1 on activated platelets during platelet thrombus formation.
In our plasma and platelet switching experiments, Δ/Δ or +/+ platelets aggregated less in Δ/Δ plasma than in normal plasma ( Figure 3A ) and the addition of rSCUBE1 improved ex vivo platelet aggregation in Δ/Δ mice ( Figure 3C ). These findings clearly indicate that lack of SCUBE1 in plasma is responsible for reduced platelet activity in Δ/Δ mice. Because SCUBE1 is also stored in the α-granules, 13 it is likely that a local concentration of SCUBE1 released after platelet activation and degranulation might further promote platelet aggregation and thrombus growth at the sites of vascular injury. However, this notion was challenged by our aggregation studies with washed platelets that showed no difference between +/+ and Δ/Δ platelets ( Figure IX in the online-only Data Supplement). Thus, locally secreted SCUBE1 derived from platelets seems not to contribute to aggregation. On the other hand, the addition of rSCUBE1 at normal plasma level Figure 6 . Inhibition of plasma signal peptide-CUB-EGF domaincontaining protein 1 (SCUBE1) protects mice against lethal thromboembolism. A, Thromboembolism induced by collagen (0.3 mg/kg) and epinephrine (60 μg/kg) treatment in +/+ mice injected with anti-SCUBE1 monoclonal antibody (mAb; 100 μg each, n=10), saline (100 μL each, n=4), or the isotype control antibody (100 μg each, n=3, P<0.05). Representative hematoxylin-eosin staining of lung cross sections from each group revealing massive thromboembolism (arrows) in mice treated with saline control (B) or isotype control antibody (C) but not in surviving SCUBE1 mAb-injected mice (D). Bar, 100 μm. E, Effect of treatment of the anti-SCUBE1-blocking antibody on tail bleeding time. The +/+ male mice (8-week-old) were injected with 100 μg of anti-SCUBE1-neutralizing antibody (n=23) or the isotype control antibody (n=25), followed by tail bleeding time test as described in the figure. Horizontal lines represent the mean. Each point represents 1 mouse. N.S. indicates not significant.
(150 ng/mL) or a higher concentration (data now shown) within the range of elevated plasma SCUBE1 levels observed in patients experiencing acute coronary syndrome or acute ischemic stroke 20 further enhanced platelet aggregation of +/+ PRP and possibly promoted pathological thrombosis ( Figure  XIIA in the online-only Data Supplement). In addition, a recent study showed a significant association of SCUBE1 polymorphism and venous thromboembolism, 23 which underscores SCUBE1 as a promising susceptible candidate gene for this type of disease.
However, the shortcoming of the global mutant mice makes it difficult to distinguish to which extent the platelet or the endothelium (or other cell types) contributes to the antithrombotic phenotype. We are currently generating a flox conditional allele that will be crossed within the Pf4-Cre (megakaryocyte/platelet-specific) or Tie2-Cre (endothelium-specific) mouse line to further dissect the relative contribution of platelets or the endothelium on the observed phenotype. Because the SCUBE protein family contains 3 different members (ie, SCUBE1 to 3) and because these molecules can be secreted and form heteromeric complexes when overexpressed, 2,7 further investigation with genetic intercrosses among Scube2-or Scube3-deficient mice is needed to confirm whether soluble forms of other SCUBEs are also involved in platelet adhesion and thrombogenesis. In addition, we noticed that triple-knockout mice deficient in other platelet adhesion proteins, including plasma fibrinogen, von Willebrand factor, and fibronectin, could still undergo platelet aggregation and thrombus formation after vascular injuries. 30 Thus, additional molecules with plasma SCUBE1 as a potential candidate may be involved in these processes.
Mouse models deficient in the ADP receptor P2Y 1 or P2Y 12, [31] [32] [33] [34] [35] von Willebrand factor receptor glycoprotein Ib-IX-V complex, 36 or the GTP-binding Gαq 37 show similar protection against fatal thromboembolism induced by collagen and epinephrine. However, in contrast to these models, our mouse model of plasma SCUBE1 deficiency did not show greatly increased bleeding time after tail clipping ( Figure 5G ). Thus, plasma SCUBE1 seems redundant for baseline hemostasis but constitutes an important platelet adhesive system in pathological thrombosis. Our findings indicate that genetic loss or inhibition of plasma SCUBE1 protected mice against fatal thromboembolism with a modest effect on bleeding. Hence, targeting plasma SCUBE1 might provide a novel therapeutic strategy to prevent thrombosis.
